MBX Biosciences, Inc. Common Stock
Symbol: MBX (NASDAQ)
Company Description:
MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include MBX 2109, MBX 1416, and MBX 4291.
- Today's Open: $10.31
- Today's High: $10.465
- Today's Low: $9.985
- Today's Volume: 98.54K
- Yesterday Close: $10.26
- Yesterday High: $11.7
- Yesterday Low: $10.225
- Yesterday Volume: 549.31K
- Last Min Volume: 34
- Last Min High: $10.14
- Last Min Low: $10.14
- Last Min VWAP: $10.14
- Name: MBX Biosciences, Inc. Common Stock
- Website: https://www.mbxbio.com
- Listed Date: 2024-09-13
- Location: CARMEL, IN
- Market Status: Active
- CIK Number: 0001776111
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $344.67M
- Round Lot: 100
- Outstanding Shares: 33.59M
- Asset Type: CS
Filing Date | Filing Type | Format |
---|---|---|
2025-09-04 | 8-K | View |
2025-08-20 | SCHEDULE 13D/A | View |
2025-08-14 | SCHEDULE 13G/A | View |
2025-08-12 | SCHEDULE 13G/A | View |
2025-08-07 | 10-Q | View |
2025-08-07 | 8-K | View |
2025-06-16 | 8-K | View |
2025-06-09 | 8-K | View |
2025-06-06 | 4 | View |
2025-06-06 | 4 | View |
2025-06-06 | 4 | View |
2025-06-06 | 4 | View |
2025-06-06 | 4 | View |
2025-06-06 | 4 | View |
2025-06-06 | 4 | View |
2025-06-06 | 8-K | View |
2025-05-12 | SCHEDULE 13G/A | View |
2025-05-12 | 10-Q | View |
2025-05-12 | 8-K | View |
2025-04-23 | ARS | View |